Can-Fite BioPharma American Depositary Shares
CANF
6 hedge funds and large institutions have $1.61M invested in Can-Fite BioPharma American Depositary Shares in 2017 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
100% more funds holding
Funds holding: 3 → 6 (+3)
1% more capital invested
Capital invested by funds: $1.59M → $1.61M (+$15K)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVH
Psagot Value Holdings
Tel Aviv,
Israel
|
+$54.9K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$38.4K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$32.9K |
| 4 |
Morgan Stanley
New York
|
+$22K |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$22K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$57K |
| 2 |
Simplex Trading
Chicago,
Illinois
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TAM
1
Taylor Asset Management
Toronto,
Ontario, Canada
| $1.43M | – | – | – |
|
|
PVH
2
Psagot Value Holdings
Tel Aviv,
Israel
| $61K | +$54.9K | +10 | +1,000% |
|
|
VKH
3
Virtu KCG Holdings
New York
| $39K | +$38.4K | +7 | New |
|
|
4
Citadel Advisors
Miami,
Florida
| $30K | +$32.9K | +6 | New |
|
|
5
Morgan Stanley
New York
| $22K | +$22K | +4 | New |
|
|
RJA
6
Raymond James & Associates
St Petersburg,
Florida
| $22K | +$22K | +4 | New |
|
|
PCM
7
Prelude Capital Management
New York
| $1K | – | – | – |
|
|
SM
8
Sabby Management
Miami Beach,
Florida
| – | -$57K | -10 | Closed |
|
|
9
Simplex Trading
Chicago,
Illinois
| – | -$1K | – | – |
|
CANF Hedge Fund Activity: Q2 2017 in Review
6 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Can-Fite BioPharma American Depositary Shares (CANF) for Q2 2017, worth a combined $1.61M — up 0.94% from $1.59M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CANF positions and 1 closed out — a net gain of 3 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Psagot Value Holdings, adding an estimated $54.9K. The largest seller was Sabby Management, exiting entirely with an estimated $57K sold.
- 6 institutional investors held Can-Fite BioPharma American Depositary Shares (CANF) as of Q2 2017, up from 3 in Q1 2017.
- Funds reported $1.61M of Can-Fite BioPharma American Depositary Shares stock for Q2 2017, up 0.94% quarter-over-quarter.
- 4 funds opened new Can-Fite BioPharma American Depositary Shares positions in Q2 2017 and 1 closed out, a net change of +3 holders.
- The largest Can-Fite BioPharma American Depositary Shares buyer in Q2 2017 was Psagot Value Holdings, an estimated $54.9K added.
- The largest Can-Fite BioPharma American Depositary Shares seller in Q2 2017 was Sabby Management, an estimated $57K sold.
Based on aggregated 13F filings for Q2 2017.